Fenspiride-d5

Fenspiride-d5 is the deuterium labeled Fenspiride. Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC50 values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases[1][2][3].

Product Specifications

CAS Number

[1246911-67-0]

UNSPSC

12352005

Target

Histamine Receptor; Isotope-Labeled Compounds; Phosphodiesterase (PDE)

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Field of Research

Inflammation/Immunology

Solubility

10 mM in DMSO

Smiles

O=C1OC2(CN1)CCN(CC2)CCC3=C([2H])C([2H])=C([2H])C([2H])=C3[2H]

Molecular Formula

C15H15D5N2O2

Molecular Weight

265.36

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Matuszewska A, et al. Long-term administration of fenspiride has no negative impact on bone mineral density and bone turnover in young growing rats. Adv Clin Exp Med. 2019 Jun;28 (6) :771-776.|[3]Cortijo J, et al. Effects of fenspiride on human bronchial cyclic nucleotide phosphodiesterase isoenzymes: functional and biochemical study. Eur J Pharmacol. 1998 Jan 2;341 (1) :79-86.|[4]De Castro CM, et al. Fenspiride: an anti-inflammatory drug with potential benefits in the treatment of endotoxemia. Eur J Pharmacol. 1995 Dec 29;294 (2-3) :669-76.